Evidence map›Paper›PMID 38562799›Full record

ArticlebioRxiv : the preprint server for biology2024

Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer.

Inga-Maria Launonen, Erdogan Pekcan Erkan, Iga Niemiec, Ada Junquera, María Hincapié-Otero, Daria Afenteva, Zhihan Liang, Matilda Salko, Angela Szabo, Fernando Perez-Villatoro and 15 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 2 countries.

Inga-Maria LaunonenResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-4548-9650
Erdogan Pekcan ErkanResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-9287-4773
Iga NiemiecResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-6134-5083
Ada JunqueraResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
María Hincapié-OteroResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-8750-1729
Daria AfentevaResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0009-0000-9596-2832
Zhihan LiangResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Matilda SalkoResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-2548-8017
Angela SzaboResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Fernando Perez-VillatoroResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-5419-8484
Matias M FalcoResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-6813-0050
Yilin LiResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.
Giulia MicoliResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0009-0003-9541-8177
Ashwini NagarajResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-9048-2116
Ulla-Maija HaltiaResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-1629-6400
Essi KahelinResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0009-0005-4518-5728
Jaana OikkonenResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-1063-2736
Johanna HynninenDepartment of Obstetrics and Gynecology, University of Turku and Turku University Hospital, Turku, Finland.ORCID 0000-0002-0854-7225
Anni VirtanenResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-7467-8434
Ajit J NirmalLaboratory of Systems Pharmacology, Harvard Medical School, Boston, USA.ORCID 0000-0003-4139-0618
Tuulia ValliusLaboratory of Systems Pharmacology, Harvard Medical School, Boston, USA.ORCID 0000-0002-3006-4887
Sampsa HautaniemiResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-7749-2694
Peter SorgerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, USA.ORCID 0000-0002-3364-1838
Anna VähärautioResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-4721-3954
Anniina FärkkiläResearch Program in Systems Oncology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-3558-6617
University of Helsinki · FIHarvard University · USUniversity of Turku · FI

Funding

Integrative Prediction of Therapeutic Response in T-cell Lymphoma by Omic and Spatial ModelingR00CA256497 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NIRMAL, AJIT JOHNSON · 2023 to 2025
$747k
NCI NIH HHS R00 CA256497
6 · The paper itself

Abstract

To uncover the intricate, chemotherapy-induced spatiotemporal remodeling of the tumor microenvironment, we conducted integrative spatial and molecular characterization of 97 high-grade serous ovarian cancer (HGSC) samples collected before and after chemotherapy. Using single-cell and spatial analyses, we identify increasingly versatile immune cell states, which form spatiotemporally dynamic microcommunities at the tumor-stroma interface. We demonstrate that chemotherapy triggers spatial redistribution and exhaustion of CD8+ T cells due to prolonged antigen presentation by macrophages, both within interconnected myeloid networks termed "Myelonets" and at the tumor stroma interface. Single-cell and spatial transcriptomics identifies prominent TIGIT-NECTIN2 ligand-receptor interactions induced by chemotherapy. Using a functional patient-derived immuno-oncology platform, we show that CD8+T-cell activity can be boosted by combining immune checkpoint blockade with chemotherapy. Our discovery of chemotherapy-induced myeloid-driven spatial T-cell exhaustion paves the way for novel immunotherapeutic strategies to unleash CD8+ T-cell-mediated anti-tumor immunity in HGSC.

Identifiers

PMID38562799
PMCPMC10983974
OpenAlexW4392978775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.